NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	RA
Date of first enrollment	02/09/2005
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : MRA (tocilizumab) INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : Intravenous infusion

Outcome(s)

Primary Outcome	Efficacy: the ability to inhibit progression of structural damage Safety: Frequency and severity of adverse events and adverse drug reactions
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 20age old
Age maximum	Not applicable
Gender
Include criteria	Inclusion criteria (1) Diagnosed as having RA, on the basis of the criteria stipulated by the American Conference on Rheumatism (ACR) in 1987. (2) At 20 years old
Exclude criteria